April 2021 tender notification
PHARMAC is pleased to provide the latest tender results.
Tender results
PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender dated 1 November 2019.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply Status, Hospital Supply Status (as relevant) commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 May 2021 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Diclofenac sodium |
Eye drops 0.1%; 5 ml OP dropper bottle |
$13.80 |
$8.80 |
Voltaren Ophtha (Novartis) |
1 June 2021 |
1 November 2021 |
|
Dorzolamide with timolol |
Eye drops 2% with timolol 0.5%; 5 ml OP dropper bottle |
$2.87 |
$2.73 |
Dortimopt (Mylan) |
1 July 2021 |
1 December 2021 |
|
Filgrastim |
Inj 300 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack |
$96.22 |
$96.22 |
Nivestim (Pfizer) |
1 July 2021 |
1 December 2021 |
|
Filgrastim |
Inj 480 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack |
$161.50 |
$148.58 |
Nivestim (Pfizer) |
1 July 2021 |
1 December 2021 |
|
Ornidazole |
Tab 500 mg, 10 tablet blister pack |
$32.95 |
$36.16 |
Arrow-Ornidazole (Teva) |
1 July 2021 |
1 December 2021 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of subsidy change |
Principal Supply date |
Brand (Supplier) affected by delisting) |
|---|---|---|---|---|---|---|---|
|
Bisacodyl |
Tab 5 mg; 200 tablet blister pack |
$5.99 |
$5.80 |
Pharmacy Health (PSM Healthcare) |
1 November 2021 |
1 April 2022 |
Lax-Tab (AFT) |
|
Lopinavir with ritonavir |
Tab 100 mg with ritonavir 25 mg; 60 tablet blister pack |
$183.75 |
$150.00 |
Lopinavir/Ritonavir Mylan (Mylan) |
1 September 2021 |
1 February 2022 |
Kaletra (AbbVie) |
|
Lopinavir with ritonavir |
Tab 200 mg with ritonavir 50 mg; 120 tablet blister pack |
$463.00 |
$295.00 |
Lopinavir/Ritonavir Mylan (Mylan) |
1 September 2021 |
1 February 2022 |
Kaletra (AbbVie) |
|
Rivastigmine |
Patch 4.6 mg per 24 hour; 30 patch pack |
$48.75 |
$38.00 |
Rivastigmine Patch BNM 5 (Boucher and Muir) |
1 September 2021 |
1 February 2022 |
Generic Partners (Generic Partners) |
|
Rivastigmine |
Patch 9.5 mg per 24 hours; 30 patch pack |
$48.75 |
$38.00 |
Rivastigmine Patch BNM 10 (Boucher and Muir) |
1 September 2021 |
1 February 2022 |
Generic Partners (Generic Partners) |
|
Varenicline tartrate |
Tab 0.5 mg x 11 and 1 mg x 42; 53 tablet blister pack |
$25.64 |
$16.67 |
Varenicline Pfizer (Pfizer) |
1 August 2021 |
1 January 2022 |
Champix (Pfizer)1 |
|
Varenicline tartrate |
Tab 1 mg; 56 tablet blister pack |
$27.10 |
$17.62 |
Varenicline Pfizer (Pfizer) |
1 August 2021 |
1 January 2022 |
Champix (Pfizer)1 |
|
1 Champix will be temporarily listed from 1 May 2021. |
|||||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Listing date |
Principal Supply Status date |
|---|---|---|---|---|---|---|---|
|
Diclofenac sodium |
Eye drops 0.1%; 5 ml dropper bottle |
$13.80 |
$8.80 |
Voltaren Ophtha (Novartis) |
5% |
1 June 2021 |
1 November 2021 |
|
Dorzolamide with timolol |
Eye drops 2% with timolol 0.5%, 5 ml dropper bottle |
$2.87 |
$2.73 |
Dortimopt (Mylan) |
5% |
1 July 2021 |
1 December 2021 |
|
Filgrastim |
Inj 300 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack |
$96.22 |
$96.22 |
Nivestim (Pfizer) |
5% |
1 July 2021 |
1 December 2021 |
|
Filgrastim |
Inj 480 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack |
$161.50 |
$148.58 |
Nivestim (Pfizer) |
5% |
1 July 2021 |
1 December 2021 |
|
Ornidazole |
Tab 500 mg, 10 tablet blister pack |
$32.95 |
$36.16 |
Arrow-Ornidazole (Teva) |
5% |
1 July 2021 |
1 December 2021 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Bisacodyl |
Tab 5 mg; 200 tablet blister pack |
$5.99 |
$5.80 |
Pharmacy Health (PSM Healthcare) |
5% |
1 November 2021 |
1 April 2022 |
Lax-Tab (AFT) |
|
Lopinavir with ritonavir |
Tab 100 mg with ritonavir 25 mg; 60 tablet blister pack |
$183.75 |
$150.00 |
Lopinavir/Ritonavir Mylan (Mylan) |
5% |
1 September 2021 |
1 February 2022 |
Kaletra (AbbVie) |
|
Lopinavir with ritonavir |
Tab 200 mg with ritonavir 50 mg; 120 tablet blister pack |
$463.00 |
$295.00 |
Lopinavir/Ritonavir Mylan (Mylan) |
5% |
1 September 2021 |
1 February 2022 |
Kaletra (AbbVie) |
|
Rivastigmine |
Patch 4.6 mg per 24 hour; 30 patch pack |
$48.75 |
$38.00 |
Rivastigmine Patch BNM 5 (Boucher and Muir) |
5% |
1 September 2021 |
1 February 2022 |
Generic Partners (Generic Partners) |
|
Rivastigmine |
Patch 9.5 mg per 24 hours; 30 patch pack |
$48.75 |
$38.00 |
Rivastigmine Patch BNM 10 (Boucher and Muir) |
5% |
1 September 2021 |
1 February 2022 |
Generic Partners (Generic Partners) |
2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
5. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Sole supply brand |
Listing date |
Sole Subsidised Supply date |
|
Tacrolimus2 |
Oint 0.1%, 30 g OP tube |
$33.00 |
Zematop (Douglas) |
1 October 2021 |
1 March 2022 |
|
2 Special Authority criteria will apply as consulted on 11 August 2020. |
|||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
6. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|
|
Tacrolimus 3 |
Oint 0.1%, 30 g tube |
$33.00 |
Zematop (Douglas) |
1% |
1 October 2021 |
1 March 2022 |
|
3 Hospital restriction criteria will apply as consulted on 11 August 2020. |
||||||
Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2020/21 Invitation to Tender, dated 2 November 2020
- the 2019/20 Invitation to Tender, dated 1 November 2019
- the 2018/19 Invitation to Tender, dated 1 November 2018
2020/21 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Atovaquone with proguanil hydrochloride |
Tab 62.5 mg with proguanil hydrochloride 25 mg |
|
Atovaquone with proguanil hydrochloride |
Tab 250 mg with proguanil hydrochloride 100 mg |
|
Budesonide |
Rectal enema 2 – 4 mg |
|
Calcium carbonate |
Orai liq |
|
Calcium carbonate |
Tab eff 0.875 – 175 g (0.5 g – 1 g elemental) |
|
Calcium gluconate |
Gel 2.5% |
|
Captopril |
Oral liq 5 mg per ml |
|
Crotamiton |
Lotn 10% |
|
Dantrolene sodium |
Cap 25 mg |
|
Dantrolene sodium |
Cap 50 mg |
|
Dantrolene sodium |
Inj |
|
Fexofenadine hydrochloride |
Tab 60 mg |
|
Fexofenadine hydrochloride |
Tab 120 mg |
|
Fexofenadine hydrochloride |
Tab 180 mg |
|
Glyceryl trinitrate |
Inj 1 mg per ml, 5 ml |
|
Glyceryl trinitrate |
Inj 1 mg per ml, 50 ml |
|
Linezolid |
Oral liq 20 mg per ml |
|
Methylprednisolone |
Tab 4 mg |
|
Methylprednisolone |
Tab 100 mg |
|
Methylprednisolone aceponate |
Crm 0.1% |
|
Methylprednisolone acetate |
Inj 40 mg per ml, 1 ml |
|
Methylprednisolone sodium |
Inj 40 mg |
|
Methylprednisolone sodium |
Inj 125 mg |
|
Methylprednisolone sodium |
Inj 500 mg |
|
Methylprednisolone sodium |
Inj 1 g |
|
Metoprolol tartrate |
Tab long-acting 200 mg |
|
Promethazine hydrochloride |
Inj 25 mg per ml, 2 ml |
|
Ticarcillin with clavulanic acid |
Inj 3 g with clavulanic acid 0.1 mg |
|
Tropisetron |
Inj 1 mg per ml, 2 ml |
|
Tropisetron |
Inj 1 mg per ml, 5 ml |
2019/20 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Clotrimazole |
Crm 1% |
|
Irbesartan |
Tab/cap 75 mg |
|
Irbesartan |
Tab/cap 150 mg |
|
Irbesartan |
Tab/cap 300 mg |
|
Irbesartan with hydrochlorothiazide |
Tab/cap 150 mg with hydrochlorothiazide 12.5 mg |
|
Irbesartan with hydrochlorothiazide |
Tab/cap 300 mg with hydrochlorothiazide 12.5 mg |
|
Irbesartan with hydrochlorothiazide |
Tab/cap 300 mg with hydrochlorothiazide 25 mg |
|
Sodium alginate with sodium bicarbonate and calcium carbonate |
Oral liq |
|
Tadalafil |
Tab/cap 2.5 mg |
|
Tadalafil |
Tab/cap 5 mg |
|
Tadalafil |
Tab/cap 10 mg |
|
Tadalafil |
Tab/cap 20 mg |
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Cefalexin |
Cap 500 mg |
|
Tenoxicam |
Inj 20 mg |
For products included in the 2018/19, 2019/20 or 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.